Increased VILIP-1 levels in cerebrospinal fluid were proposed as diagnostic and prognostic biomarkers of neuroinflammation and cognitive decline in patients with AD, dementia with Lewy bodies, or frontotemporal lobar degeneration [47–53]. Here, VSNL1 is linked to Alzheimer disease.